Skip to main content
Atrás
TBPH logo

Theravance Biopharma, Inc.

Calidad de datos: 100%
TBPH
NASDAQ Healthcare Biotechnology
$15.29
▲ $0.39 (2.62%)
Cap. Mercado: 780.84M
Rango del Día
$14.95 $15.36
Rango de 52 Semanas
$7.90 $21.03
Volumen
483,971
Promedio 50D / 200D
$17.97 / $15.18
Cierre Anterior
$14.90

Quick Summary

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (631 pares)

Métrica Acción Mediana del Sector
P/E 7.4 0.2
P/B 2.6 3.0
ROE % 44.9 3.6
Net Margin % 98.5 3.8
Rev Growth 5Y % 18.1 9.9
D/E 0.1 0.2

Precio Objetivo de Analistas

Hold
$27.00 +76.6%
Low: $14.00 High: $40.00
P/E Futuro
7.33
EPS Futuro
$2.09
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
115.70M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $1.01
$0.75 – $1.54
 100.62M 2
FY2029 $0.85
$0.63 – $1.29
 96.09M 4
FY2028 $0.76
$0.09 – $1.51
 92.05M 6

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-19 $1.09 $0.06 -94.5%
2025-11-10 -$0.03 $0.04 +233.3%
2025-08-12 -$0.14 -$0.08 +42.9%
2025-05-08 -$0.11 -$0.17 -54.5%
2025-02-26 -$0.05 -$0.05 0.0%
2024-11-12 -$0.10 -$0.06 +40.0%
2024-08-05 -$0.09 -$0.13 -44.4%
2024-05-13 -$0.19 -$0.09 +52.6%

Insider Trading Activity

17 transactions
Date Insider Type Shares Price Value
Feb 20, 2026
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 74,975 $19.66 $1,474,008.50
Feb 20, 2026
Sawaf Aziz
SVP & CHIEF FINANCIAL OFFICER
 other 20,672 $19.66 $406,411.52
Feb 20, 2026
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
 other 13,929 $19.66 $273,844.14
Feb 20, 2026
Miller Aine
SVP, DEV & HEAD OF IRE OFFICE
 other 16,851 $19.66 $331,290.66
Nov 20, 2025
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
 other 9,060 $17.90 $162,174.00
Nov 20, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 56,817 $17.90 $1,017,024.30
Nov 19, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 19,800 — —
Aug 20, 2025
Sawaf Aziz
SVP & CHIEF FINANCIAL OFFICER
 other 9,368 $13.39 $125,437.52
Aug 20, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 15,394 $13.39 $206,125.66
Aug 20, 2025
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
 other 9,096 $13.39 $121,795.44
Aug 20, 2025
Miller Aine
SVP, DEV & HEAD OF IRE OFFICE
 other 6,989 $13.39 $93,582.71
Jun 23, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 20,000 — —
Jun 2, 2025
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
 sell 24,000 $11.00 $264,000.00
May 20, 2025
Sawaf Aziz
SVP & CHIEF FINANCIAL OFFICER
 other 9,348 $9.45 $88,338.60
May 20, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 15,364 $9.45 $145,189.80
May 19, 2025
GRAY SUSANNAH
 grant 34,907 — —
May 19, 2025
Smaldone Alsup Laurie
 grant 34,907 — —

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Puntos Clave

Revenue grew 18.06% annually over 5 years — strong growth
ROE of 44.85% indicates high profitability
Net margin of 98.54% shows strong profitability
Debt/Equity of 0.14 — conservative balance sheet
Generating 238.50M in free cash flow
P/E of 7.37 — trading at a low valuation

Crecimiento

Revenue Growth (5Y)
18.06%
Revenue (1Y)66.92%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
44.85%
ROIC-0.80%
Net Margin98.54%
Op. Margin-3.35%

Seguridad

Debt / Equity
0.14
Current Ratio10.93
Interest Coverage-1.46

Valoración

P/E Ratio
7.37
Forward P/E7.33
P/B Ratio2.63
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 66.92% Revenue Growth (3Y) 36.80%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 18.06% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 107.46M Net Income (TTM) 105.90M
ROE 44.85% ROA 21.81%
Gross Margin 94.87% Operating Margin -3.35%
Net Margin 98.54% Free Cash Flow (TTM) 238.50M
ROIC -0.80% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.14 Current Ratio 10.93
Interest Coverage -1.46
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 7.37 Forward P/E 7.33
P/B Ratio 2.63 P/S Ratio 7.27
PEG Ratio -0.03 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 6.75 Fwd Earnings Yield 13.64%
FCF Yield 30.54%
Market Cap 780.84M Enterprise Value 655.74M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 107.46M 64.38M 57.42M 51.35M 55.31M
Net Income 105.90M -56.42M -55.19M 872.13M -199.43M
EPS (Diluted) 2.06 -1.15 -1.00 -1.26 -2.87
Gross Profit 101.95M 64.38M 16.80M -12.05M -138.35M
Operating Income -3.60M -46.95M -56.04M -91.96M -257.78M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 485.57M 354.16M 382.00M 607.40M 374.82M
Total Liabilities 188.85M 178.62M 169.00M 165.60M 713.39M
Shareholders' Equity 296.72M 175.55M 213.00M 441.80M -338.57M
Total Debt 42.70M 49.82M 49.16M 52.16M 669.52M
Cash & Equivalents 167.81M 37.80M 39.55M 298.17M 89.96M
Current Assets 418.46M 161.07M 133.54M 353.46M 249.87M
Current Liabilities 38.30M 32.09M 24.77M 28.72M 58.59M

Puntuaciones de Estrategias

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#157 of 1049
65
Custom Capital Light Compounder
#7 of 219
75
Value Value Investing (Warren Buffett)
#9 of 203
53

Actividad Reciente

Salió Contrarian Investing (David Dreman)
Mar 26, 2026
Entró Cash Flow Compounder
Mar 24, 2026
Entró Capital Light Compounder
Mar 24, 2026
Entró Contrarian Investing (David Dreman)
Mar 24, 2026
Entró Value Investing (Warren Buffett)
Mar 24, 2026